FDA: Genitope must continue vaccine tests

Genitope's hopes of bringing its MyVax cancer vaccine to market quickly were dashed Monday when an independent board recommended that a clinical trial of its cancer vaccine continue. Although the 300-patient trial was scheduled to end in 2007, Genitope believed its vaccine might produce results sooner. The vaccine for an incurable form of non-Hodgkin's lymphoma, a blood cancer, is Genitope's most advanced product. The news took a bite out of its stock value this morning.

- read this story from the Los Angeles Times for more